CONGRESS FOR VOTERS

Earl Carter (R-GA)

FDA Modernization Act 3.0

H.R. 2821 · House bill Health

A Republican bill with 21 Democratic cosponsors · See all 41 cosponsors

Last activity — Received in the Senate.

Passed one chamber, waiting for the other to take it up

Passed one chamber, and the other has not yet sent it to a committee or put it on its calendar.

The other chamber will hand it to a committee, place it on its calendar, or leave it where it is. Nothing has been decided, and a bill can sit here indefinitely.

Its path through Congress

  1. Introduced
  2. Passed House voice vote
  3. Awaiting Senate

The House by voice vote (members called out yes or no together): no member's position on it was recorded.

What this bill would do

The FDA Modernization Act 3.0 requires the Secretary of Health and Human Services, via the Commissioner of Food and Drugs, to publish an interim final rule. This rule aims to implement previous amendments to the Federal Food, Drug, and Cosmetic Act. It directs the replacement of specific references to "animal" tests, data, and research with "nonclinical" terms within various sections of title 21 of the Code of Federal Regulations. The act also mandates adding the definition of "nonclinical test" to several specific regulatory sections. Additionally, the bill includes a technical amendment regarding the designation of subsections within the Federal Food, Drug, and Cosmetic Act.

Yes

  • Scored +5

    Does this better protect air, water and wildlife?

    The shift toward nonclinical methods may reduce the reliance on animal testing.

The opposite

No question was scored the opposite.